Abstract 534P
Background
Lung cancer is a major health concern worldwide. It is the leading cause of cancer-related deaths among both men and women. The current study aims to investigate the role of desmocollin 2 (DSC2) protein in the proliferation, migration, drug resistance and immunotherapy of lung cancer cells. Lung cancer is a major health concern worldwide.
Methods
To examine the role of DSC2 in lung cancer cells, various assays were performed, including CCK-8 and colony formation assays to assess the impact on cell viability and colony formation, respectively. Transwell and wound-healing assays were also conducted to evaluate the impact on cell migration. The flow cytometry double staining assay was employed to detect the apoptosis rate of cells with DSC2 added with cisplatin. Western blotting analysis was used to examine the levels of cell cycle, PI3k/Akt, and apoptosis-related proteins.
Results
The results of this study revealed that DSC2 is upregulated in clinical lung cancer tissues compared to pericarcinomatous tissues and differentially expressed in lung cancer cell lines. The down-regulation of DSC2 in A549 and H358 lung cancer cells significantly reduced cell proliferation, metastasis, and motility. In addition to lung adenocarcinoma cell lines, we also examined its expression in lung squamous cell lines, such as H226. However, the overexpression of DSC2 in H23 and PC9 cell lines showed opposite effects. Western blotting showed that DSC2 could reduce the level of phosphorylated Akt (Ser 473) and p-mTOR. Thus, the study suggested that DSC2 up-regulation promotes proliferation and invasiveness through activation of the PI3K/AKT pathway. DSC2 knockdown can significantly decrease the levels of cyclinB and wee1 protein in A549 and H226. Cisplatin combined with DSC2 knockdown can enhance cell apoptosis rates.
Conclusions
These data suggest that dsc2 promotes the proliferation and migration of lung cancer cells in vitro. Also, the results suggested that dsc2 could affect the cell cycle and apoptosis of lung cells. Furthermore, knockdown of dsc2 could sensitize cisplatin in both lung adenocarcinoma and lung squamous cell lines. Thus, we suggested that dsc2 can be used as a therapeutic target for lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Affiliated Hangzhou First People’s Hospital of Zhejiang university.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood
Presenter: HEE SEON Kim
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract